vs
Ginkgo Bioworks Holdings, Inc.（DNA）与OR Royalties Inc.（OR）财务数据对比。点击上方公司名可切换其他公司
OR Royalties Inc.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.4倍（$46.7M vs $33.4M）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
OR Royalties Inc.是一家加拿大矿业特许权企业，持有金矿、银矿及钻石矿的特许权权益，主要以冶炼厂净回报权和金属流形式运营。其前身为奥西斯科矿业，总部位于魁北克省蒙特利尔，股票在多伦多证券交易所及纽约证券交易所挂牌交易。
DNA vs OR — 直观对比
营收规模更大
OR
是对方的1.4倍
$33.4M
损益表 — Q4 FY2025 vs Q2 FY2022
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $46.7M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | — |
| 净利率 | — | — |
| 营收同比 | -23.8% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAOR
| Q4 25 | $33.4M | — | ||
| Q3 25 | $38.8M | — | ||
| Q2 25 | $49.6M | — | ||
| Q1 25 | $48.3M | — | ||
| Q4 24 | $43.8M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $56.2M | — | ||
| Q1 24 | $37.9M | — |
净利润DNAOR
| Q4 25 | — | — | ||
| Q3 25 | $-80.8M | — | ||
| Q2 25 | $-60.3M | — | ||
| Q1 25 | $-91.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | — | ||
| Q2 24 | $-217.2M | — | ||
| Q1 24 | $-165.9M | — |
营业利润率DNAOR
| Q4 25 | -211.9% | — | ||
| Q3 25 | -231.8% | — | ||
| Q2 25 | -132.1% | — | ||
| Q1 25 | -184.1% | — | ||
| Q4 24 | -236.3% | — | ||
| Q3 24 | -62.0% | — | ||
| Q2 24 | -396.7% | — | ||
| Q1 24 | -469.1% | — |
净利率DNAOR
| Q4 25 | — | — | ||
| Q3 25 | -207.9% | — | ||
| Q2 25 | -121.6% | — | ||
| Q1 25 | -188.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | — | ||
| Q2 24 | -386.4% | — | ||
| Q1 24 | -437.3% | — |
每股收益（稀释后）DNAOR
| Q4 25 | $-1.41 | — | ||
| Q3 25 | $-1.45 | — | ||
| Q2 25 | $-1.10 | — | ||
| Q1 25 | $-1.68 | — | ||
| Q4 24 | $-1.91 | — | ||
| Q3 24 | $-1.08 | — | ||
| Q2 24 | $-4.23 | — | ||
| Q1 24 | $-3.32 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | $222.8M |
| 股东权益账面价值 | $508.6M | $1.3B |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资DNAOR
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
股东权益DNAOR
| Q4 25 | $508.6M | — | ||
| Q3 25 | $559.8M | — | ||
| Q2 25 | $613.0M | — | ||
| Q1 25 | $647.4M | — | ||
| Q4 24 | $716.1M | — | ||
| Q3 24 | $797.9M | — | ||
| Q2 24 | $833.1M | — | ||
| Q1 24 | $987.3M | — |
总资产DNAOR
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | — |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | — |
| 自由现金流率自由现金流/营收 | -142.8% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DNAOR
| Q4 25 | $-47.7M | — | ||
| Q3 25 | $-31.6M | — | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-51.5M | — | ||
| Q4 24 | $-42.4M | — | ||
| Q3 24 | $-103.5M | — | ||
| Q2 24 | $-84.4M | — | ||
| Q1 24 | $-89.3M | — |
自由现金流DNAOR
| Q4 25 | $-47.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-59.1M | — | ||
| Q4 24 | $-56.1M | — | ||
| Q3 24 | $-118.6M | — | ||
| Q2 24 | $-111.4M | — | ||
| Q1 24 | $-96.0M | — |
自由现金流率DNAOR
| Q4 25 | -142.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -81.2% | — | ||
| Q1 25 | -122.4% | — | ||
| Q4 24 | -128.0% | — | ||
| Q3 24 | -133.2% | — | ||
| Q2 24 | -198.2% | — | ||
| Q1 24 | -252.9% | — |
资本支出强度DNAOR
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 31.3% | — | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 17.7% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
OR
暂无分部数据
